Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 Back to Details

Connection

Ruud Dings to Animals

This is a "connection" page, showing publications Ruud Dings has written about Animals.

 
Connection Strength
  
 
 
1.066
  
  1. Jenkins SV, Shah S, Jamshidi-Parsian A, Mortazavi A, Kristian H, Boysen G, Vang KB, Griffin RJ, Rajaram N, Dings RPM. Acquired Radiation Resistance Induces Thiol-dependent Cisplatin Cross-resistance. Radiat Res. 2024 02 01; 201(2):174-187.
    View in: PubMed
    Score: 0.079
  2. Jenkins SV, Alimohammadi M, Terry AS, Griffin RJ, Tackett AJ, Leung JW, Vang KB, Byrum SD, Dings RPM. Dysbiotic stress increases the sensitivity of the tumor vasculature to radiotherapy and c-Met inhibitors. Angiogenesis. 2021 08; 24(3):597-611.
    View in: PubMed
    Score: 0.065
  3. Jenkins SV, Robeson MS, Griffin RJ, Quick CM, Siegel ER, Cannon MJ, Vang KB, Dings RPM. Gastrointestinal Tract Dysbiosis Enhances Distal Tumor Progression through Suppression of Leukocyte Trafficking. Cancer Res. 2019 12 01; 79(23):5999-6009.
    View in: PubMed
    Score: 0.059
  4. Jenkins SV, Vang KB, Gies A, Griffin RJ, Jun SR, Nookaew I, Dings RPM. Sample storage conditions induce post-collection biases in microbiome profiles. BMC Microbiol. 2018 12 27; 18(1):227.
    View in: PubMed
    Score: 0.056
  5. Dings RPM, Miller MC, Griffin RJ, Mayo KH. Galectins as Molecular Targets for Therapeutic Intervention. Int J Mol Sci. 2018 Mar 19; 19(3).
    View in: PubMed
    Score: 0.053
  6. Koonce NA, Griffin RJ, Dings RPM. Galectin-1 Inhibitor OTX008 Induces Tumor Vessel Normalization and Tumor Growth Inhibition in Human Head and Neck Squamous Cell Carcinoma Models. Int J Mol Sci. 2017 Dec 09; 18(12).
    View in: PubMed
    Score: 0.052
  7. Dings RP, Haseman JR, Leslie DB, Luong M, Dunn DL, Mayo KH. Bacterial membrane disrupting dodecapeptide SC4 improves survival of mice challenged with Pseudomonas aeruginosa. Biochim Biophys Acta. 2013 Jun; 1830(6):3454-7.
    View in: PubMed
    Score: 0.037
  8. Dings RP, Levine JI, Brown SG, Astorgues-Xerri L, MacDonald JR, Hoye TR, Raymond E, Mayo KH. Polycationic calixarene PTX013, a potent cytotoxic agent against tumors and drug resistant cancer. Invest New Drugs. 2013 Oct; 31(5):1142-50.
    View in: PubMed
    Score: 0.037
  9. Dings RP, Kumar N, Miller MC, Loren M, Rangwala H, Hoye TR, Mayo KH. Structure-based optimization of angiostatic agent 6DBF7, an allosteric antagonist of galectin-1. J Pharmacol Exp Ther. 2013 Mar; 344(3):589-99.
    View in: PubMed
    Score: 0.037
  10. Dings RP, Miller MC, Nesmelova I, Astorgues-Xerri L, Kumar N, Serova M, Chen X, Raymond E, Hoye TR, Mayo KH. Antitumor agent calixarene 0118 targets human galectin-1 as an allosteric inhibitor of carbohydrate binding. J Med Chem. 2012 Jun 14; 55(11):5121-9.
    View in: PubMed
    Score: 0.035
  11. Dings RP, Vang KB, Castermans K, Popescu F, Zhang Y, Oude Egbrink MG, Mescher MF, Farrar MA, Griffioen AW, Mayo KH. Enhancement of T-cell-mediated antitumor response: angiostatic adjuvant to immunotherapy against cancer. Clin Cancer Res. 2011 May 15; 17(10):3134-45.
    View in: PubMed
    Score: 0.032
  12. Dings RP, Loren ML, Zhang Y, Mikkelson S, Mayo KH, Corry P, Griffin RJ. Tumour thermotolerance, a physiological phenomenon involving vessel normalisation. Int J Hyperthermia. 2011; 27(1):42-52.
    View in: PubMed
    Score: 0.032
  13. Dings RP, Van Laar ES, Webber J, Zhang Y, Griffin RJ, Waters SJ, MacDonald JR, Mayo KH. Ovarian tumor growth regression using a combination of vascular targeting agents anginex or topomimetic 0118 and the chemotherapeutic irofulven. Cancer Lett. 2008 Jul 08; 265(2):270-80.
    View in: PubMed
    Score: 0.027
  14. Dings RP, Loren M, Heun H, McNiel E, Griffioen AW, Mayo KH, Griffin RJ. Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization. Clin Cancer Res. 2007 Jun 01; 13(11):3395-402.
    View in: PubMed
    Score: 0.025
  15. Dings RP, Chen X, Hellebrekers DM, van Eijk LI, Zhang Y, Hoye TR, Griffioen AW, Mayo KH. Design of nonpeptidic topomimetics of antiangiogenic proteins with antitumor activities. J Natl Cancer Inst. 2006 Jul 05; 98(13):932-6.
    View in: PubMed
    Score: 0.023
  16. Dings RP, Williams BW, Song CW, Griffioen AW, Mayo KH, Griffin RJ. Anginex synergizes with radiation therapy to inhibit tumor growth by radiosensitizing endothelial cells. Int J Cancer. 2005 Jun 10; 115(2):312-9.
    View in: PubMed
    Score: 0.022
  17. Jenkins SV, Johnsrud AJ, Dings RPM, Griffin RJ. Bystander Effects in Spatially Fractionated Radiation Therapy: From Molecule To Organism To Clinical Implications. Semin Radiat Oncol. 2024 Jul; 34(3):284-291.
    View in: PubMed
    Score: 0.020
  18. Jenkins SV, Jung S, Jamshidi-Parsian A, Borrelli MJ, Dings RPM, Griffin RJ. Morphological Effects and In Vitro Biological Mechanisms of Radiation-Induced Cell Killing by Gold Nanomaterials. ACS Appl Mater Interfaces. 2023 Dec 20; 15(50):58241-58250.
    View in: PubMed
    Score: 0.020
  19. Dings RP, van der Schaft DW, Hargittai B, Haseman J, Griffioen AW, Mayo KH. Anti-tumor activity of the novel angiogenesis inhibitor anginex. Cancer Lett. 2003 May 08; 194(1):55-66.
    View in: PubMed
    Score: 0.019
  20. Dings RP, Yokoyama Y, Ramakrishnan S, Griffioen AW, Mayo KH. The designed angiostatic peptide anginex synergistically improves chemotherapy and antiangiogenesis therapy with angiostatin. Cancer Res. 2003 Jan 15; 63(2):382-5.
    View in: PubMed
    Score: 0.018
  21. Dings RP, Nesmelova I, Griffioen AW, Mayo KH. Discovery and development of anti-angiogenic peptides: A structural link. Angiogenesis. 2003; 6(2):83-91.
    View in: PubMed
    Score: 0.018
  22. Safina I, Al Sudani ZAN, Hashoosh A, Darrigues E, Watanabe F, Biris AS, Dings RPM, Bao Vang K. Gold nanorods enhance different immune cells and allow for efficient targeting of CD4+ Foxp3+ Tregulatory cells. PLoS One. 2021; 16(8):e0241882.
    View in: PubMed
    Score: 0.017
  23. Safina I, Alghazali KM, Childress L, Griffin C, Hashoosh A, Kannarpady G, Watanabe F, Bourdo SE, Dings RPM, Biris AS, Vang KB. Dendritic cell biocompatibility of ether-based urethane films. J Appl Toxicol. 2021 09; 41(9):1456-1466.
    View in: PubMed
    Score: 0.016
  24. Johnsrud AJ, Jenkins SV, Jamshidi-Parsian A, Quick CM, Galhardo EP, Dings RPM, Vang KB, Narayanasamy G, Makhoul I, Griffin RJ. Evidence for Early Stage Anti-Tumor Immunity Elicited by Spatially Fractionated Radiotherapy-Immunotherapy Combinations. Radiat Res. 2020 12 01; 194(6):688-697.
    View in: PubMed
    Score: 0.016
  25. Dadgar S, Troncoso JR, Siegel ER, Curry NM, Griffin RJ, Dings RPM, Rajaram N. Spectroscopic investigation of radiation-induced reoxygenation in radiation-resistant tumors. Neoplasia. 2021 01; 23(1):49-57.
    View in: PubMed
    Score: 0.016
  26. Jenkins SV, Nedosekin DA, Shaulis BJ, Wang T, Jamshidi-Parsian A, Pollock ED, Chen J, Dings RPM, Griffin RJ. Enhanced Photothermal Treatment Efficacy and Normal Tissue Protection via Vascular Targeted Gold Nanocages. Nanotheranostics. 2019; 3(2):145-155.
    View in: PubMed
    Score: 0.014
  27. Paidi SK, Diaz PM, Dadgar S, Jenkins SV, Quick CM, Griffin RJ, Dings RPM, Rajaram N, Barman I. Label-Free Raman Spectroscopy Reveals Signatures of Radiation Resistance in the Tumor Microenvironment. Cancer Res. 2019 04 15; 79(8):2054-2064.
    View in: PubMed
    Score: 0.014
  28. Boysen G, Jamshidi-Parsian A, Davis MA, Siegel ER, Simecka CM, Kore RA, Dings RPM, Griffin RJ. Glutaminase inhibitor CB-839 increases radiation sensitivity of lung tumor cells and human lung tumor xenografts in mice. Int J Radiat Biol. 2019 04; 95(4):436-442.
    View in: PubMed
    Score: 0.014
  29. Nowak-Sliwinska P, Alitalo K, Allen E, Anisimov A, Aplin AC, Auerbach R, Augustin HG, Bates DO, van Beijnum JR, Bender RHF, Bergers G, Bikfalvi A, Bischoff J, B?ck BC, Brooks PC, Bussolino F, Cakir B, Carmeliet P, Castranova D, Cimpean AM, Cleaver O, Coukos G, Davis GE, De Palma M, Dimberg A, Dings RPM, Djonov V, Dudley AC, Dufton NP, Fendt SM, Ferrara N, Fruttiger M, Fukumura D, Ghesqui?re B, Gong Y, Griffin RJ, Harris AL, Hughes CCW, Hultgren NW, Iruela-Arispe ML, Irving M, Jain RK, Kalluri R, Kalucka J, Kerbel RS, Kitajewski J, Klaassen I, Kleinmann HK, Koolwijk P, Kuczynski E, Kwak BR, Marien K, Melero-Martin JM, Munn LL, Nicosia RF, Noel A, Nurro J, Olsson AK, Petrova TV, Pietras K, Pili R, Pollard JW, Post MJ, Quax PHA, Rabinovich GA, Raica M, Randi AM, Ribatti D, Ruegg C, Schlingemann RO, Schulte-Merker S, Smith LEH, Song JW, Stacker SA, Stalin J, Stratman AN, Van de Velde M, van Hinsbergh VWM, Vermeulen PB, Waltenberger J, Weinstein BM, Xin H, Yetkin-Arik B, Yla-Herttuala S, Yoder MC, Griffioen AW. Consensus guidelines for the use and interpretation of angiogenesis assays. Angiogenesis. 2018 08; 21(3):425-532.
    View in: PubMed
    Score: 0.014
  30. Koonce NA, Juratli MA, Cai C, Sarimollaoglu M, Menyaev YA, Dent J, Quick CM, Dings RPM, Nedosekin D, Zharov V, Griffin RJ. Real-time monitoring of circulating tumor cell (CTC) release after nanodrug or tumor radiotherapy using in?vivo flow cytometry. Biochem Biophys Res Commun. 2017 10 21; 492(3):507-512.
    View in: PubMed
    Score: 0.013
  31. Vang KB, Safina I, Darrigues E, Nedosekin D, Nima ZA, Majeed W, Watanabe F, Kannarpady G, Kore RA, Casciano D, Zharov VP, Griffin RJ, Dings RPM, Biris AS. Modifying Dendritic Cell Activation with Plasmonic Nano Vectors. Sci Rep. 2017 07 14; 7(1):5513.
    View in: PubMed
    Score: 0.013
  32. Jenkins SV, Nedosekin DA, Miller EK, Zharov VP, Dings RPM, Chen J, Griffin RJ. Galectin-1-based tumour-targeting for gold nanostructure-mediated photothermal therapy. Int J Hyperthermia. 2018 02; 34(1):19-29.
    View in: PubMed
    Score: 0.012
  33. Koonce NA, Levy J, Hardee ME, Jamshidi-Parsian A, Vang KB, Sharma S, Raleigh JA, Dings RP, Griffin RJ. Targeting Artificial Tumor Stromal Targets for Molecular Imaging of Tumor Vascular Hypoxia. PLoS One. 2015; 10(8):e0135607.
    View in: PubMed
    Score: 0.011
  34. Koonce NA, Quick CM, Hardee ME, Jamshidi-Parsian A, Dent JA, Paciotti GF, Nedosekin D, Dings RP, Griffin RJ. Combination of Gold Nanoparticle-Conjugated Tumor Necrosis Factor-a and Radiation Therapy Results in a Synergistic Antitumor Response in Murine Carcinoma Models. Int J Radiat Oncol Biol Phys. 2015 Nov 01; 93(3):588-96.
    View in: PubMed
    Score: 0.011
  35. L?ppchen T, Dings RP, Rossin R, Simon JF, Visser TJ, Bakker M, Walhe P, van Mourik T, Donato K, van Beijnum JR, Griffioen AW, Lub J, Robillard MS, Mayo KH, Gr?ll H. Novel analogs of antitumor agent calixarene 0118: Synthesis, cytotoxicity, click labeling with 2-[(18)F]fluoroethylazide, and in vivo evaluation. Eur J Med Chem. 2015 Jan 07; 89:279-95.
    View in: PubMed
    Score: 0.010
  36. Griffin RJ, Koonce NA, Dings RP, Siegel E, Moros EG, Br?uer-Krisch E, Corry PM. Microbeam radiation therapy alters vascular architecture and tumor oxygenation and is enhanced by a galectin-1 targeted anti-angiogenic peptide. Radiat Res. 2012 Jun; 177(6):804-12.
    View in: PubMed
    Score: 0.009
  37. Song CW, Lee H, Dings RP, Williams B, Powers J, Santos TD, Choi BH, Park HJ. Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells. Sci Rep. 2012; 2:362.
    View in: PubMed
    Score: 0.009
  38. Griffin RJ, Dings RP, Jamshidi-Parsian A, Song CW. Mild temperature hyperthermia and radiation therapy: role of tumour vascular thermotolerance and relevant physiological factors. Int J Hyperthermia. 2010; 26(3):256-63.
    View in: PubMed
    Score: 0.007
  39. Saarinen NM, W?rri A, Dings RP, Airio M, Smeds AI, M?kel? S. Dietary lariciresinol attenuates mammary tumor growth and reduces blood vessel density in human MCF-7 breast cancer xenografts and carcinogen-induced mammary tumors in rats. Int J Cancer. 2008 Sep 01; 123(5):1196-204.
    View in: PubMed
    Score: 0.007
  40. Schumacher JJ, Dings RP, Cosin J, Subramanian IV, Auersperg N, Ramakrishnan S. Modulation of angiogenic phenotype alters tumorigenicity in rat ovarian epithelial cells. Cancer Res. 2007 Apr 15; 67(8):3683-90.
    View in: PubMed
    Score: 0.006
  41. Amano M, Suzuki M, Andoh S, Monzen H, Terai K, Williams B, Song CW, Mayo KH, Hasegawa T, Dings RP, Griffin RJ. Antiangiogenesis therapy using a novel angiogenesis inhibitor, anginex, following radiation causes tumor growth delay. Int J Clin Oncol. 2007 Feb; 12(1):42-7.
    View in: PubMed
    Score: 0.006
  42. Chen X, Dings RP, Nesmelova I, Debbert S, Haseman JR, Maxwell J, Hoye TR, Mayo KH. Topomimetics of amphipathic beta-sheet and helix-forming bactericidal peptides neutralize lipopolysaccharide endotoxins. J Med Chem. 2006 Dec 28; 49(26):7754-65.
    View in: PubMed
    Score: 0.006
  43. Hellebrekers DM, Castermans K, Vir? E, Dings RP, Hoebers NT, Mayo KH, Oude Egbrink MG, Molema G, Fuks F, van Engeland M, Griffioen AW. Epigenetic regulation of tumor endothelial cell anergy: silencing of intercellular adhesion molecule-1 by histone modifications. Cancer Res. 2006 Nov 15; 66(22):10770-7.
    View in: PubMed
    Score: 0.006
  44. Thijssen VL, Postel R, Brandwijk RJ, Dings RP, Nesmelova I, Satijn S, Verhofstad N, Nakabeppu Y, Baum LG, Bakkers J, Mayo KH, Poirier F, Griffioen AW. Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc Natl Acad Sci U S A. 2006 Oct 24; 103(43):15975-80.
    View in: PubMed
    Score: 0.006
  45. Brandwijk RJ, Dings RP, van der Linden E, Mayo KH, Thijssen VL, Griffioen AW. Anti-angiogenesis and anti-tumor activity of recombinant anginex. Biochem Biophys Res Commun. 2006 Oct 27; 349(3):1073-8.
    View in: PubMed
    Score: 0.006
  46. van Beijnum JR, Dings RP, van der Linden E, Zwaans BM, Ramaekers FC, Mayo KH, Griffioen AW. Gene expression of tumor angiogenesis dissected: specific targeting of colon cancer angiogenic vasculature. Blood. 2006 Oct 01; 108(7):2339-48.
    View in: PubMed
    Score: 0.006
  47. Dirkx AE, oude Egbrink MG, Castermans K, van der Schaft DW, Thijssen VL, Dings RP, Kwee L, Mayo KH, Wagstaff J, Bouma-ter Steege JC, Griffioen AW. Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors. FASEB J. 2006 Apr; 20(6):621-30.
    View in: PubMed
    Score: 0.006
  48. Thijssen VL, Brandwijk RJ, Dings RP, Griffioen AW. Angiogenesis gene expression profiling in xenograft models to study cellular interactions. Exp Cell Res. 2004 Oct 01; 299(2):286-93.
    View in: PubMed
    Score: 0.005
  49. Wild R, Dings RP, Subramanian I, Ramakrishnan S. Carboplatin selectively induces the VEGF stress response in endothelial cells: Potentiation of antitumor activity by combination treatment with antibody to VEGF. Int J Cancer. 2004 Jun 20; 110(3):343-51.
    View in: PubMed
    Score: 0.005
  50. Wild R, Yokoyama Y, Dings RP, Ramakrishnan S. VEGF-DT385 toxin conjugate inhibits mammary adenocarcinoma development in a transgenic mouse model of spontaneous tumorigenesis. Breast Cancer Res Treat. 2004 May; 85(2):161-71.
    View in: PubMed
    Score: 0.005
  51. Mayo KH, Dings RP, Flader C, Nesmelova I, Hargittai B, van der Schaft DW, van Eijk LI, Walek D, Haseman J, Hoye TR, Griffioen AW. Design of a partial peptide mimetic of anginex with antiangiogenic and anticancer activity. J Biol Chem. 2003 Nov 14; 278(46):45746-52.
    View in: PubMed
    Score: 0.005
  52. van der Schaft DW, Dings RP, de Lussanet QG, van Eijk LI, Nap AW, Beets-Tan RG, Bouma-Ter Steege JC, Wagstaff J, Mayo KH, Griffioen AW. The designer anti-angiogenic peptide anginex targets tumor endothelial cells and inhibits tumor growth in animal models. FASEB J. 2002 Dec; 16(14):1991-3.
    View in: PubMed
    Score: 0.005
  53. Tromp SC, oude Egbrink MG, Dings RP, van Velzen S, Slaaf DW, Hillen HF, Tangelder GJ, Reneman RS, Griffioen AW. Tumor angiogenesis factors reduce leukocyte adhesion in vivo. Int Immunol. 2000 May; 12(5):671-6.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.